These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9249219)

  • 21. Amphotericin B lipid complex: in visceral leishmaniasis.
    Goldsmith DR; Perry CM
    Drugs; 2004; 64(17):1905-11; discussion 1912-3. PubMed ID: 15329037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
    Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
    Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
    Moreau P; Milpied N; Fayette N; Ramée JF; Harousseau JL
    J Antimicrob Chemother; 1992 Oct; 30(4):535-41. PubMed ID: 1490923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversy in the regimens of treatment with amphotericin B in resistant cases of kala-azar.
    Thakur CP
    J Assoc Physicians India; 1995 Nov; 43(11):813-4. PubMed ID: 8773056
    [No Abstract]   [Full Text] [Related]  

  • 26. Amphotericin B: the higher the dose, the higher the toxicity.
    Pasqualotto AC
    Clin Infect Dis; 2008 Oct; 47(8):1110; author reply 1110-1. PubMed ID: 18800934
    [No Abstract]   [Full Text] [Related]  

  • 27. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
    Joly V; Geoffray C; Reynes J; Goujard C; Méchali D; Maslo C; Raffi F; Yeni P
    J Antimicrob Chemother; 1996 Jul; 38(1):117-26. PubMed ID: 8858463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comment: compatibility of amphotericin B with lipid emulsions.
    Montoro JB; López RM; Pou L
    Ann Pharmacother; 1996 Dec; 30(12):1501. PubMed ID: 8968472
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
    Frothingham R
    Clin Infect Dis; 2002 Oct; 35(7):896-7; author reply 897-8. PubMed ID: 12228830
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis.
    Harrison TS
    Clin Infect Dis; 2009 Jun; 48(12):1784-6. PubMed ID: 19441979
    [No Abstract]   [Full Text] [Related]  

  • 34. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
    Altmannsberger P; Holler E; Andreesen R; Krause SW
    J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
    Coukell AJ; Brogden RN
    Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.
    Pandey K; Pal B; Siddiqui NA; Rabi Das VN; Murti K; Lal CS; Verma N; Babu R; Ali V; Kumar R; Das P
    Am J Trop Med Hyg; 2017 Nov; 97(5):1498-1502. PubMed ID: 29016288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B.
    Mishra M
    J Assoc Physicians India; 1995 Apr; 43(4):306. PubMed ID: 8713286
    [No Abstract]   [Full Text] [Related]  

  • 39. Poor immediate tolerability of amphotericin B lipid emulsion in patients with haematological malignancies. Haematology-Microbiology Group.
    Laverdière M; Habel F; Weiss K; Delorme J; Dubois G; Gagnon N; Bélanger R
    J Antimicrob Chemother; 1997 Dec; 40(6):910-2. PubMed ID: 9462450
    [No Abstract]   [Full Text] [Related]  

  • 40. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.